Historical lly News Stories
LLY Surge: Orna Deal, Orforglipron FDA Moment Now!
Eli Lilly (LLY) saw fresh tailwinds this week as the company expanded into in vivo CAR‑T via the Orna Therapeutics acquisition, navigated acquisition chatter around Ventyx, and approaches a critical FDA decision for oral orforglipron. Early prescription data for Novo’s oral Wegovy and renewed technical momentum in LLY shares frame near‑term upside and volatility for investors.
Lilly Rises as Novo Trial Fails, GLP-1 Lead Widens
Eli Lilly gained market momentum after Novo Nordisk’s late‑stage CagriSema failure, reinforcing Lilly’s leadership in GLP‑1 obesity treatments. Combined with Lilly’s confidence in an oral GLP‑1 pill, a $3.5 billion Pennsylvania manufacturing investment, and analyst EPS upgrades, these concrete developments are reshaping near‑term growth expectations while regulatory pricing pressures remain a key risk.
Lilly: Price Caps Cut Obesity Margins; FDA NearFeb
In the past week Eli Lilly has faced a concrete policy and regulatory crossroads: new U.S. price caps and Medicare coverage for obesity drugs compress margins, while an FDA decision on Lilly’s oral GLP-1 candidate orforglipron is imminent. Meanwhile, a potential €15 billion Abivax acquisition and ongoing M&A moves illustrate management’s push to diversify beyond weight-loss franchises.
Lilly Surge: $3.5B Plant & Record 2026 Outlook Now
Eli Lilly (LLY) gained momentum this week after announcing a $3.5B Lehigh Valley manufacturing complex, issuing a bullish $80–$83B 2026 revenue guide driven by tirzepatide sales, and benefiting from regulatory moves that reduced low-cost competition. These concrete developments underpin near-term growth and investor confidence in LLY within the S&P 500.
Lilly Acquires Orna; GLP-1 Sales Drive Q4 Jump Now
Eli Lilly’s $2.4B buy of Orna Therapeutics and a blockbuster GLP‑1 quarter — driven by Mounjaro and Zepbound — underscore the company’s shift into cell and genetic therapies while sustaining outsized revenue growth. Strong Q4 results, bullish 2026 guidance, and an advancing oral GLP‑1 program combine with industry price competition to shape LLY’s near-term outlook.